GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (OTCPK:CPHI) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

China Pharma Holding (China Pharma Holding) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Jun. 10, 2024)


View and export this data going back to 2002. Start your Free Trial

What is China Pharma Holding Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, China Pharma Holding's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of China Pharma Holding's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Pharma Holding's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where China Pharma Holding's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.


China Pharma Holding  (OTCPK:CPHI) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

China Pharma Holding Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

China Pharma Holding (China Pharma Holding) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (OTCPK:CPHI) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
ECGS HENC BFRI PRFX CLVR CNNC EVOK JUVAF LSDI STEK ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX
Traded in Other Exchanges
N/A
Address
Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216
Website
https://www.chinapharmaholdings.com
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Executives
Ke Deng 10 percent owner NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216
Frank Waung officer: Chief Financial Officer 72 GREAT HILLS RD., SHORT HILLS NJ 07078
G Michael Bennett director 4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600
Yingwen Zhang director NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041
Baowen Dong director NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041
Heung Mei Tsui director, 10 percent owner FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX
Zhilin Li officer: President and CEO 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216
Jian Yang officer: Secretary NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216
Xinhua Wu officer: CFO 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216
George L Diamond 10 percent owner 174 FM 1830, ARGYLE TX 76226
David F Brigante 10 percent owner 174FM 1830, ARGYLE TX 76226
Marat Rosenberg 10 percent owner 17 FM 1830, ARGYLE TX 76226
Halter Financial Investments Lp 10 percent owner 174 FM 1830, ARGYLE TX 76226
Halter Financial Investments Gp Llc 10 percent owner 174 FM 1830, ARGYLE TX 76226
Timothy P Halter director, 10 percent owner, officer: CEO, President & CFO 174 FM 1830, ARGYLE TX 76226